Development of novel therapies that specifically target the NLRP3 inflammasome may therefore provide an effective treatment to reduce the mortality associated with pathogenic IAV, and offset the ineffectiveness of current antiviral treatments in the later stages of infection. The gene discussed is NLRP3; the disease is infection.